research use only
Cat.No.S5754
| Related Targets | EGFR STAT Pim |
|---|---|
| Other JAK Inhibitors | BMS-986165 (Deucravacitinib) AZD1480 WP1066 Filgotinib (GLPG0634) Momelotinib (CYT387) AT9283 Gandotinib (LY2784544) Pacritinib (SB1518) NVP-BSK805 2HCl TG101209 |
|
In vitro |
DMSO
: 94 mg/mL
(200.25 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 469.41 | Formula | C16H20N7O6PS |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1187595-84-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | INCB-028050 phosphate, LY-3009104 phosphate | SMILES | CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
JAK2
(Cell-free assay) 5.7 nM
JAK1
(Cell-free assay) 5.9 nM
TYK2
(Cell-free assay) 53 nM
JAK3
(Cell-free assay) >400 nM
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2026-09-04)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07222137 | RECRUITING | Diabetes Mellitus, Type 1 |
Eli Lilly and Company |
2026-01-12 | PHASE3 |
| NCT03773965 | RECRUITING | Juvenile Idiopathic Arthritis |
Eli Lilly and Company |
2019-04-05 | PHASE3 |
| NCT06923072 | RECRUITING | Kohlmeier-Degos Disease; Malignant Atrophic Papulosis; Degos Disease; Papulosis, Malignant Atrophic |
National Heart, Lung, and Blood Institute (NHLBI) |
2026-02-18 | PHASE2 |
| NCT07543458 | NOT_YET_RECRUITING | Dengue; Severe Dengue; Mosquito-Borne Diseases; Vector Borne Diseases; Arbovirus Infections; Flavivirus Infections; RNA Virus Infections; Hemorrhagic Fever |
Oxford University Clinical Research Unit, Vietnam |
2026-10-01 | PHASE3 |
| NCT07262983 | RECRUITING | Hyper IgE Syndrome From STAT3 Mutation; Job s Syndrome; HIES; Lupus; Atopic Dermatitis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2026-09-09 | PHASE1 |
| NCT07003997 | RECRUITING | Major Depressive Disorder |
Emory University |
2025-09-03 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.